secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0001213900-23-054758
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron appoints Dr. Nataliya Agafonova as CMO, effective July 1, 2023
-------------------------------------------------------------------------

- Dr. Agafonova replaces Dr. K. Chris Min, who stepped down as CMO on June 30, 2023.
- She will lead global clinical development and regulatory strategy.
- Agafonova previously served as Clinical Development Lead at Otsuka Pharmaceutical and Bristol-Myers Squibb.
- A consulting agreement with hourly cash fee is in place until full-time employment begins on or about July 24, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/0001213900-23-054758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023054758/ea181311-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-054758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer